• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.

作者信息

Howell Matthew, Gibb Adam, Radford John, Linton Kim

机构信息

Department of Medical Oncology, The Christie NHS Foundation Trust, Withington, Manchester, M20 4BX, UK.

Manchester Academic Health Science Centre, The University of Manchester, Manchester, M13 9NT, UK.

出版信息

Br J Haematol. 2017 Dec;179(5):841-843. doi: 10.1111/bjh.14257. Epub 2016 Jul 22.

DOI:10.1111/bjh.14257
PMID:27447404
Abstract
摘要

相似文献

1
Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.苯达莫司汀可作为复发的、对本妥昔单抗难治的霍奇金淋巴瘤进行异基因移植的桥梁。
Br J Haematol. 2017 Dec;179(5):841-843. doi: 10.1111/bjh.14257. Epub 2016 Jul 22.
2
Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.复发或难治性霍奇金淋巴瘤患者接受本妥昔单抗治疗失败后单药苯达莫司汀的安全性和有效性：27例患者的经验
Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):404-8. doi: 10.1016/j.clml.2015.02.023. Epub 2015 Mar 5.
3
Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.原发性难治性或复发性经典霍奇金淋巴瘤患者应用本妥昔单抗维泊妥珠单抗联合苯达莫司汀桥接自体造血干细胞移植的真实世界疗效。
Ann Hematol. 2020 Oct;99(10):2385-2392. doi: 10.1007/s00277-020-04204-1. Epub 2020 Aug 3.
4
Bendamustine as a bridge to allogeneic transplant in relapsed/refractory Hodgkin lymphoma patients who failed salvage brentuximab vedotin postautologous peripheral blood stem cell transplantation.苯达莫司汀作为复发/难治性霍奇金淋巴瘤患者异基因移植的桥梁，这些患者在自体外周血干细胞移植后接受挽救性本妥昔单抗治疗失败。
Leuk Lymphoma. 2017 Nov;58(11):2745-2747. doi: 10.1080/10428194.2017.1307362. Epub 2017 Mar 28.
5
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.苯达莫司汀对复发/难治性 Brentuximab vedotin 的霍奇金淋巴瘤患者的疗效。
Br J Haematol. 2013 Dec;163(5):681-3. doi: 10.1111/bjh.12548. Epub 2013 Aug 30.
6
Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.复发/难治性霍奇金淋巴瘤自体移植前，以本妥昔单抗作为二线治疗的多中心II期试验结果。
Biol Blood Marrow Transplant. 2015 Dec;21(12):2136-2140. doi: 10.1016/j.bbmt.2015.07.018. Epub 2015 Jul 26.
7
Brentuximab Vedotin in Combination With Dacarbazine or Bendamustine for Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Multi-Cohort Phase 2 Study.本妥昔单抗联合达卡巴嗪或苯达莫司汀用于60岁及以上患者霍奇金淋巴瘤一线治疗：多队列2期研究的中期结果
Clin Adv Hematol Oncol. 2016 Feb;14(2 Suppl 1):13-5.
8
The addition of bendamustine to brentuximab vedotin leads to improved rates of complete metabolic remission in children, adolescents and young adults with relapsed and refractory classical Hodgkin lymphoma: a retrospective single-centre series.在复发难治性经典型霍奇金淋巴瘤的儿童、青少年和年轻成人中，将苯达莫司汀添加到维布妥昔单抗中可提高完全代谢缓解率：一项回顾性单中心研究系列。
Br J Haematol. 2021 Feb;192(3):e84-e87. doi: 10.1111/bjh.17274. Epub 2021 Jan 10.
9
Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany.在英国和德国，接受自体干细胞移植后复发/难治性霍奇金淋巴瘤患者中，维布妥昔单抗对比医生选择的化疗方案的真实世界有效性。
Leuk Lymphoma. 2018 Jun;59(6):1413-1419. doi: 10.1080/10428194.2017.1382698. Epub 2017 Oct 18.
10
Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma.本妥昔单抗联合苯达莫司汀用于复发或难治性霍奇金淋巴瘤的儿科患者或年轻成人。
Pediatr Blood Cancer. 2022 Apr;69(4):e29557. doi: 10.1002/pbc.29557. Epub 2022 Feb 2.

引用本文的文献

1
Optimizing outcomes in relapsed/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies.复发性/难治性霍奇金淋巴瘤的治疗效果优化：当前及未来治疗策略综述
Ther Adv Hematol. 2020 Feb 16;11:2040620720902911. doi: 10.1177/2040620720902911. eCollection 2020.
2
Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab.与B细胞慢性淋巴细胞白血病无克隆相关性的经典霍奇金淋巴瘤增殖性疾病采用苯达莫司汀联合利妥昔单抗治疗成功
Cancers (Basel). 2018 Sep 3;10(9):304. doi: 10.3390/cancers10090304.
3
Nivolumab salvage therapy before or after allogeneic stem cell transplantation in Hodgkin lymphoma.
霍奇金淋巴瘤异基因干细胞移植前后的纳武单抗挽救治疗。
Bone Marrow Transplant. 2017 Jul;52(7):1074-1077. doi: 10.1038/bmt.2017.69. Epub 2017 Apr 10.